For the first time, our study reveals that elevated GFPT2 expression is correlated with poor clinical outcomes in LUSC, suggesting that the PD-1 inhibitor combined with SMI may prolong patient survival in NSCLC by decreasing the proportion of GFPT2+ CAFs. Here, PDCD1 is linked to non-small cell lung carcinoma.